HER2-POSITIVE EARLY BREAST CANCER
Clinical trials for HER2-POSITIVE EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo could spare chemo for some breast cancer patients
Disease control Recruiting nowThis study tests a personalized treatment plan for people with HER2-positive early breast cancer. It compares a newer drug (trastuzumab-deruxtecan) against standard chemotherapy combinations to see which works better and causes fewer side effects. About 702 participants will rece…
Matched conditions: HER2-POSITIVE EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: West German Study Group • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New breast cancer trial adapts treatment based on early response
Disease control Recruiting nowThis phase 2 trial is for people with HER2-positive early breast cancer. After initial standard therapy, those who don't respond well will switch to a stronger combination of newer drugs, including trastuzumab-rezetecan and pyrotinib. The goal is to see if this personalized appro…
Matched conditions: HER2-POSITIVE EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC